Study results released in the US overnight show the new vaccine cocktail produces 1.75 times as many antibodies against Omicron as its original shot.The new vaccine was tested in the US against the original Omicron variant BA.1 that swept through Australia over the Christmas holidays.There is no data on whether it will work against the latest Omicron variants BA.4 and BA.5 variants now sweeping the country.A new clinical trial by Moderna gave 377 people who‘d had three previous vaccinations a fourth dose of the company’s original vaccine.And it compared their outcomes to 437 people also given three previous jabs who were given a new combination shot aimed at the original form of the virus as well as Omicron.The newer vaccine led to a nearly eight-fold rise in levels of antibodies capable of fighting Omicron.And it produced an antibody jump 1.75 times better than giving a fourth dose of the original vaccine, Moderna said.The company said it was submitting the trial data to US regulator the FDA and hoped to market it around the end of summer in the US.“We anticipate more durable protection against variants of concern with mRNA-1273.214, making it our lead candidate for a Fall 2022 booster,” said Stéphane Bancel, Chief Executive Officer of Moderna.“We are submitting our preliminary data and analysis to regulators with the hope that the Omicron-containing bivalent booster will be available in the late summer,” she said.Moderna has entered a partnership with the Australian Government to build a manufacturing plant in Melbourne capable of producing 100 million mRNA vaccines a year.It is possible the latest version of its Covid vaccine could be made here.While the fast paced development of the Omicron version of the vaccine is unheard of, the virus is still managing to outpace science.Even before the vaccine targeted at the original Omicron was fully tested the virus had mutated again to become even more infectious.
Powered by WPeMatico
